Together with an off-trial use and off-track access to oncology therapies, a consolidated trend is reported in clinical practice despite the uncertainties on efficacy and safety
Applications in artificial intelligence have the potential to transform precision oncology, but data quality and clinical validation of tools are still challenging
Using treatments only where clear benefit has been demonstrated and modulating doses based on evidence are potentially effective strategies to reduce the rising costs of oncology
Recent research shows that tailored strategies and political commitment can revert current epidemiology trends of cancer
The rapidly increasing integration of AI into many aspects of breast cancer management calls for urgent definition of expected levels of evidence and bespoke regulatory and reimbursement processes
Clinical trials have an impact on the environment, and novel approaches may help researchers reshape their activities toward a greater sustainability
Universal health coverage in oncology is still not a reality, as a recent report shows
Personalised proteogenomics has the power to transform the identification, staging and management of NSCLC in never smokers
Despite recent progress, lung cancer remains deadly and difficult to treat — and preventable, to a much greater extent with the right actions to improve the quality of the air we breathe
ESMO is sustaining its efforts to give rare cancers a more prominent place in oncology
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.